Destiny Pharma PLC undervalued compared to peers, suggests finnCap
"Phase 3 trial design is due to be finalised in H1 2022, which should catalyse partnering discussions.“ Destiny Pharma’s 29021...
"Phase 3 trial design is due to be finalised in H1 2022, which should catalyse partnering discussions.“ Destiny Pharma’s 29021...
